Business Context and Reporting Period
This Form 8-K is filed by Manhattan Pharmaceuticals, Inc. (noted as TG THERAPEUTICS, INC. in metadata) on March 23, 2007. The report addresses a notice from the American Stock Exchange (Amex) regarding the Company's compliance with continued listing standards.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures for the current period. However, it references the following financial conditions cited by the Amex as grounds for non-compliance:
- Stockholders' Equity: Less than $4,000,000 (violating Section 1003(a)(ii)) and less than $6,000,000 (violating Section 1003(a)(iii)).
- Losses: The Company reported losses from continuing operations and/or net losses in three of its four most recent fiscal years and in its five most recent fiscal years.
Material Changes and Listing Status
On January 12, 2007, the Company received notice of non-compliance with Amex listing standards due to low equity and recurring losses. On March 23, 2007, the Amex staff determined that the Company had made a reasonable demonstration of its ability to regain compliance by the end of the plan period, April 16, 2008. The Company is now required to provide regular progress updates to the Amex staff.
Outlook, Risks, and Contingencies
Compliance Plan: The Company submitted a plan on February 8, 2007, to address the listing deficiencies.
Risk of Delisting: If the Amex staff determines the Company is not making progress consistent with the plan, it may be subject to delisting proceedings.
Monitoring: The Amex staff will continue to monitor the Company's compliance with the plan through April 16, 2008.
Investor Verification Checklist
- Verify the Company's current stockholders' equity to ensure it meets the $4,000,000 and $6,000,000 thresholds.
- Review the Company's financial performance for the most recent fiscal years to confirm the trend of losses.
- Monitor future filings for updates on the Company's progress toward the April 16, 2008 compliance deadline.
- Check for any subsequent notices from the Amex regarding potential delisting proceedings.